Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Rucker

Internal Medicine Durand, WI Medical Doctor

NPI 1326088642 CMS profile 104848

1250 Third Ave West, Durand, WI 54736

Open in the dashboard

General payments

$3,129

209 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Rucker of Durand, WI is reported in the CMS Open Payments database as having received $3,129 across 209 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $506 32
2024 General $525 31
2023 General $593 32
2022 General $321 20
2021 General $175 12
2020 General $221 17
2019 General $789 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Rucker
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kenneth Rucker were reported at $506. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kenneth Rucker Internal Medicine median Middle half National median
2019 $789 $159 $48–$570 $163
2020 $221 $119 $33–$402 $114
2021 $175 $135 $37–$521 $132
2022 $321 $141 $42–$496 $149
2023 $593 $149 $45–$519 $160
2024 $525 $154 $47–$537 $164
2025 $506 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $929 56 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $662 43 payments
  3. Amgen Inc. $285 19 payments
  4. Pfizer Inc. $204 19 payments
  5. Novartis Pharmaceuticals Corporation $185 12 payments
  6. Novo Nordisk Inc $172 10 payments
  7. Janssen Pharmaceuticals, Inc $145 10 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $126 11 payments
  9. E.R. Squibb & Sons, L.L.C. $97 5 payments
  10. Lilly USA, LLC $65 5 payments
  11. Other $258 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,118 208 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. QULIPTA $620 29 payments
  2. TRADJENTA $578 38 payments
  3. JARDIANCE Diabetes $391 28 payments
  4. SYNJARDY $295 19 payments
  5. GLYXAMBI $196 15 payments
  6. ENTRESTO $185 12 payments
  7. EVENITY $152 10 payments
  8. ELIQUIS $151 12 payments
  9. XARELTO $145 10 payments
  10. JARDIANCE Diabetes $138 7 payments
  11. Other $2,331 169 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 159 drugs

Part D claims

10,426

Median for Internal Medicine: 777

Drug cost

$555,832

Median for Internal Medicine: $73,373

Branded share of claims

18.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 232 $157,060
Trulicity Dulaglutide Brand 62 $61,439
Jardiance Empagliflozin Brand 70 $41,151
Xarelto Rivaroxaban Brand 62 $32,235
Ozempic Semaglutide Brand 24 $22,958
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 25 $15,724
Incruse Ellipta Umeclidinium Bromide Brand 39 $13,943
Myrbetriq Mirabegron Brand 25 $12,025
Mounjaro Tirzepatide Brand 11 $11,595
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 13 $8,399

The 10 drugs with the highest cost, of 159 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$12,060

Medicare's payments for the services billed

Medicare patients

110

Average age 80

Services billed

537

62 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 46%
Heart failure 40%
Atrial fibrillation 40%
Diabetes 35%
Chronic kidney disease 35%
Depression 29%
Alzheimer's or dementia 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $135
$135 — —
VRAYLAR
  • AbbVie, Inc. $78
$78 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $68
$68 232 —
UBRELVY
  • AbbVie, Inc. $46
$46 — —
SYNJARDY
  • Boehringer Ingelheim Pharmaceuticals, Inc. $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record